CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BKRASMutationPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaBrugger et al., 2011
DPIK3CAH1047RPredictiveSupportsResistanceColorectal CancerVemurafenibYang et al., 2012
BBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibRutkowski et al., 2015
BBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibUgurel et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseChildhood Pilocytic AstrocytomaVemurafenibdel Bufalo et al., 2014
CBRAFV600EPredictiveSupportsSensitivity/ResponseOvarian Serous CarcinomaVemurafenibCombe et al., 2015
BEGFRMutationPrognosticSupportsBetter OutcomeLung AdenocarcinomaBrugger et al., 2011
BEGFRMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibPao et al., 2004
CEGFRL861QPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
DEGFRT790MPredictiveSupportsResistanceCancerGefitinib,Multikinase Inhibitor AEE788,ErlotinibKancha et al., 2009
DEGFRL858RPredictiveSupportsSensitivity/ResponseCancerGefitinib,Multikinase Inhibitor AEE788,ErlotinibKancha et al., 2009
BBCR::ABL1Fusion AND ABL1 F359VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
CKRASG12VPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
CBRAFV600EPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
CPIK3CAR88QPredictiveDoes Not SupportResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CPIK3CAH1047RPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CNRASG12CPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
CPIK3CAG1049RPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BKRASA146TPredictiveSupportsResistanceColorectal CancerCetuximab,FOLFOX-4 RegimenKaczirek et al., 2015
CKRASQ61HPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
CKRASQ61LPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
CKRASQ61RPredictiveSupportsResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
CKRASQ61KPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
BKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BKRASMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinibBrugger et al., 2011
BKRASA146PredictiveDoes Not SupportResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
DKRASG12DPredictiveSupportsResistanceOvarian CancerCetuximabSato et al., 2012
BKRASG12CPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
CKRASG12RPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
BKRASG12SPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BAKT1S473 PhosphorylationPrognosticDoes Not SupportPoor OutcomeColorectal CancerKato et al., 2007
BKITExon 11 MutationPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
CKITW557_K558delPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
DKITW557_K558delPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorPonatinib,ImatinibGarner et al., 2014
CKITExon 9 MutationPredictiveSupportsReduced SensitivityGastrointestinal Stromal TumorRegorafenib AnhydrousBen-Ami et al., 2016
CKITV560DPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
DKITV560DPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorPonatinib,Regorafenib Anhydrous,Sunitinib,ImatinibGarner et al., 2014
DKITN822KPredictiveDoes Not SupportResistanceGastrointestinal Stromal TumorPonatinibGarner et al., 2014
DKITW557_K558del AND KIT N822KPredictiveSupportsResistanceCancerRegorafenib AnhydrousGarner et al., 2014
BBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibUgurel et al., 2015
BBRAFV600KPredictiveSupportsSensitivity/ResponseSkin MelanomaDabrafenib,TrametinibRobert et al., 2015
DEGFRR108KPredictiveSupportsSensitivity/ResponseHigh Grade GliomaErlotinibLee et al., 2006
DEGFRT263PPredictiveSupportsSensitivity/ResponseHigh Grade GliomaErlotinibLee et al., 2006
DEGFRA289VPredictiveSupportsSensitivity/ResponseHigh Grade GliomaErlotinibLee et al., 2006
BEGFRG719PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibWu et al., 2011
CEGFRG719DPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibWu et al., 2011
CEGFRV774APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
CEGFRV834IPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
CEGFRL838PPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
DEGFRL858RPredictiveSupportsSensitivity/ResponseCancerErlotinibde Gunst et al., 2007
Page 43 of 96
PreviousNext